Inotrem
Biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€20—30m (Dealroom.co estimates Feb 2020.)
Company register number 791682172
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | <1m | - | - | - | <1m | - |
| EBITDA | (3.9m) | (4.0m) | (4.8m) | (6.8m) | (12.8m) | (17.6m) |
| % EBITDA margin | (101277 %) | - | - | - | (7740758 %) | - |
| Profit | (3.2m) | (3.5m) | (4.1m) | (5.5m) | (11.5m) | (15.5m) |
| % profit margin | (82734 %) | - | - | - | (6949372 %) | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Support Program | |
€18.0m | Series A | ||
* | €39.0m | Series B | |
$5.5m | Series B | ||
€45.0m | Grant | ||
* | N/A | Grant | |
* | N/A | Grant | |
| Total Funding | €107m | ||
Related Content
Recent News about Inotrem
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.